1.SCI's major business is including below three (3) items:
（1）APIs, API intermediates, special and Custom Synthesis (Development , manufacturing)（2）Supporting for bidding and distribution of products from domestic and overseas manufacturers as a local partner.
（3）Represent for Development of products in item 2.
2. Sales
Unit：NTD in thousand| Product | Y2023 | Ratio |
| API | 718,312 | 55.65% |
| Intermediate | 471,644 | 39.17% |
| Others | 14,203 | 1.18% |
| Total | 1,204,159 | 100.00% |
3.Product list and Services：
| Category | Product list |
|
API
| VA Probucol Divalproate Sodium Propafenone Hydrochloride Duloxetine Hydrochloride Allopurinol Clindamycin palmitate HCl Articaine Hydrochloride HOCLQ-Sulfate Brinzolamide Sodium Valproate Pentobarbital Sodium Methylphenidate HCl Biso-FA必 Thiopental acid Loxoprofen Sodium Hydrate Atomoxetine HCl Cannabidiol Adenine Buprenorphine |
|
Intermediates | DEDPM |
| Specialty Chemical | DEK... etc. total in 7 items |
4. Sales volume/value in the most recent 2 years:
Unit: Ton / Unit: thousand NT$
| Year | 2022 | 2023 | ||||||
|---|---|---|---|---|---|---|---|---|
| Sales Volume/Value | Domestic Sales | Export | Domestic Sales | Export | ||||
| Primary Product | Volume | Value | Volume | Value | Volume | Value | Volume | Value |
| APIs | 50.16 | 101,413 | 133.90 | 348,810 | 50.03 | 83.441 | 2800.80 | 6345,852 |
| API intermediates | 0.40 | 1,166 | 123.81 | 432,196 | 0 | 0 | 121.96 | 471,634 |
| Others | 181.66 | 6,740 | (18.98) | 9,413 | 125.27 | 12,777 | 0 | 1,426 |
| Total | 232.22 | 109,319 | 238.73 | 790,419 | 176.30 | 96,238 | 322.76 | 1,107,921 |